DMRA:NASDAQDamora Therapeutics, Inc. Analysis
Data as of 2026-08-26 - not real-time
$30.62
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Damora Therapeutics, Inc. is priced at $30.62 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it lost 1.2%. With RSI at 52.9 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near $28.16 and resistance around $33.56.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 45.9% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 50.5%, a beta of 2.05 and a maximum drawdown of 72.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 45.9% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 50.5%, a beta of 2.05 and a maximum drawdown of 72.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 1/10 conviction.
Top Market Events
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin mutCALR -driven...Yahoo Finance15dDamora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate...Yahoo Finance22dDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 c 4 BOSTON, Aug.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 25.65
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 25.65
- Analyst targets imply +45.9% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +45.9% versus the current price
- Negative return on equity of -99.7%
- Negative free cash flow
Key Metrics & Analysis
Financial Health
P/E Ratio-14.3
ROE-99.74%
ROA-21.61%
P/B Ratio4.9
Op. Cash Flow$-44515000
Free Cash Flow$-15979875
Industry P/E31.2
Technical Analysis
TrendBullish
RSI52.9
Support$28.16
Resistance$33.56
MA 20$30.29
MA 50$28.49
MA 200$25.65
MACDBearish
VolumeDecreasing
Fear & Greed Index93.39
Valuation
Target Price$44.67
Upside/Downside45.87%
GradeFair
TypeGrowth
Risk Assessment
Beta2.05
Volatility50.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.